Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00068718 · OUTCOME

Overall Survival

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant · Source last updated 2020-01-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
1 year after DLI

What was measured

Percentage patients surviving 1 year post-transplant.

Groups in this outcome

Treatment (DLI)

Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented. Therapeutic Allogeneic Lymphocytes: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (DLI)35

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (DLI)71.4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        71.4
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
description
Percentage patients surviving 1 year post-transplant.
groups
  1. description
    Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented. Therapeutic Allogeneic Lymphocytes: Given IV
    id
    OG000
    title
    Treatment (DLI)
param Type
NUMBER
reporting Status
POSTED
time Frame
1 year after DLI
title
Overall Survival
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice